Moderna and Merck stock surges 90% following successful cancer vaccine trial
Shares of US companies Moderna and Merck climbed by up to 90% on Wednesday following news that their custom-made cancer vaccine achieved primary objectives in a significant late-stage study. The treatment boosted recurrence-free survival rates for 1,137 patients diagnosed with high-risk Stage IIB-IV melanoma who had previously undergone surgery to remove their tumors. Following the announcement, Moderna stock climbed 91% to reach $120.26, while Merck saw its share price increase by 9%.
by shortkt.com✓